TVM Capital Steps up Its Involvement in Riemser Arzneimittel AG – GE Healthcare Financial Services Also Acquires an Interest in the Company

MUNICH & FRANKFURT & RIEMS, Germany--(BUSINESS WIRE)--Munich-based investor TVM Capital and GE Healthcare Financial Services now jointly hold 25.4% of shares in Riemser Arzneimittel AG, with the remaining 74.6% owned by the Braun family. TVM Capital gained a 10% share in the medium-sized pharmaceutical company located on Riems Island in Mecklenburg-Vorpommern at the end of last year.

“We are looking forward to furthering systematically the impressive development of Riemser AG. The growth strategy pursued by the management can now be implemented even faster and lead the company towards further market successes”

Together with the new shareholders, the firm’s management, led by CEO Norbert Braun, will continue to pursue its international growth and specialization strategy with determination. In the words of Dr Christoph Schröder, TVM Capital partner and a member of Riemser’s Supervisory Board, “We are looking forward to furthering systematically the impressive development of Riemser AG. The growth strategy pursued by the management can now be implemented even faster and lead the company towards further market successes”.

According to Theo Weber, Director of GE Healthcare Financial Services Deutschland, “The main focus of our investment policy in the healthcare and pharmaceuticals sector, combined with GE’s capacity to cover the full range of financing services, make GE Healthcare Financial Services the perfect partner for investing in Riemser Arzneimittel AG, together with TVM Capital”.

Additional editorial information:

TVM Capital

TVM Capital, founded in 1983 as Techno Venture Management, is one of the first venture capital firms formed in Germany and was an early entrant into the US market in 1986. Since its launch, TVM Capital has raised more than EUR 1.3 billion in six fund generations and has established itself as one of the leading VC companies in Europe. TVM Capital funds have made investments in some 240 technology and life science companies in Europe and the US – sectors where innovation, effective management and sound financial backing have a major impact on company growth. The firm’s in-depth knowledge of the European and international market environment provides TVM Capital portfolio companies with access to research, science and capital, and helps the international development of management and distribution channels. More than 50 TVM Capital-backed companies have gone public on European or US stock exchanges. Today, TVM Capital is actively invested in over 70 companies. For more information, visit: www.tvm-capital.com

GE Healthcare Financial Services

GE Healthcare Financial Services is the leading provider of financial solutions for the healthcare market. With over $17 billion in assets, GE Healthcare Financial Services offers a full range of financing capabilities from equipment leasing and real estate financing to working capital lending and acquisition financing. With its experience and in-depth knowledge of the healthcare industry, GE Healthcare Financial Services offers its customers tailored financial solutions. For more information, visit: www.gehealthcarefinance.com/europe

RIEMSER Arzneimittel AG

RIEMSER Arzneimittel AG is a pharmaceutical company located in Greifswald on Riems Island, in Mecklenburg-Vorpommen. RIEMSER AG operates several companies in Germany, producing anti-inflammatory, dermatological and dental drugs as well as medication to treat tumorous and immunological diseases. The firm’s research and development partners are renowned research institutes and universities in Germany and Europe. Research partners in Mecklenburg-Vorpommern include the Medical Faculty Institutes of the Universities of Rostock and Greifswald as well as the renowned Riems Island Friedrich Loeffler Institute (FLI). For more information, visit: www.riemser.de

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.